A 2026 consumer research report examining the Medicinal Garden Kit, the 'backyard pharmacy' herbal gardening concept, ...
March 9, Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First ...
Time Walker on MSN
Traditional shops continue daily trade in China
This video shows a historic street in Suzhou, China, where traditional shops continue their daily trade. Many stores display herbs and ingredients commonly used in Chinese medicine and cooking. Red ...
Foundation Medicine launches its Whole Genome Sequencing Germline test for research use to support translational research and drug discovery.
Ghana News Agency on MSN
Traditional bitters: Craft of merging plant-based medicine with local gin
By Miriam Oparebea, GNA Tema, March 11, GNA – Herbs have long been regarded as important sources of healing in many Ghanaian communities, where plant roots, barks, leaves and other parts are boiled, ...
Geek Spin on MSN
Why your next prescription might be made in space
The next time you pick up a prescription, its secret to success might not have been discovered in a lab on Earth, but on a station orbiting 250 miles above it. While it sounds like science fiction, ...
Discover how commercial space stations will replace the ISS, fuel the post ISS space industry, and unlock new opportunities for research, tourism, and in-orbit manufacturing.
An analysis of two large cohort studies finds that carriers of disease-causing variants within genes for three ...
A rugged hiker standing atop a jagged peak, sweat-drenched and triumphant, looking like they just finished filming a high-budget energy drink commercial. This image does not feel like an invitation to ...
Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established ...
Multiplex assay tech detects multi-biomolecules in single samples on xMAP/CBA, with high sensitivity and consistency ...
Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results